Spatial Immune Profiling and AI-Based Classifiers Identify Predictors of BCG Therapy Outcomes in High-Risk Non-Muscle-Invasive Bladder Cancer
Authors:
- Melinda LillesandMLMelinda Lillesand
- Marie AustdalMAMarie Austdal
- Jakub MrozJMJakub Mroz
- Ivar SkalandISIvar Skaland
- Einar GudlaugssonEGEinar Gudlaugsson
- Florus C. de JongFJFlorus C. de Jong
- Tahlita C. M. ZuiverloonTahlita C. M. Zuiverloon
- Kjersti EnganKEKjersti Engan
- Emiel A. M. JanssenEJEmiel A. M. Janssen
Open Access
Abstract
Background/Objectives: High recurrence rates and intensive lifelong surveillance make bladder cancer among the costliest malignancies to treat. Although Bacillus Calmette–Guérin (BCG) immunotherapy is the standard treatment for high-risk non-muscle-invasive bladder cancer (NMIBC), up to 50% of patients fail to respond, and predictive biomarkers are lacking. Molecular profiling has established three BCG response subtypes (BRS1–3), with BRS3 characterized by an immunosuppressive, BCG-resistant phenotype; however, these features have not been validated at single-cell spatial resolution. Methods: We applied imaging mass cytometry (IMC) to 82 BCG-treated high-risk NMIBC samples and performed (i) single-cell IMC with unsupervised clustering to identify phenotypic cell clusters and quantify cluster abundances and (ii) a convolutional neural network-based gated attention multiple instance learning model trained on IMC images (IMC-GA-MIL) to predict BCG response. Cluster abundances were summarized using II (immune composition within the immune compartment), TT (tumor phenotypic composition), and IT (immune/stromal abundance relative to tumor cells) indices. Results: Single-cell IMC identified 18 distinct phenotypic cell clusters. In BCG responders, immune cells localized within the tumor compartment were enriched and independently protective (HR 0.67, 95% CI 0.49–0.92). BCG nonresponse was associated with a higher abundance of fibroblast-dominant clusters relative to tumor cells (IT index). Plasma cell-dominant clusters were the strongest predictors of progression (II index HR 2.28, 95% CI 1.37–3.79; IT index HR 1.25, 95% CI 1.06–1.48). The IMC-GA-MIL model predicted BCG response with 90% accuracy (9/10) and identified myeloid- and T-cell-associated marker patterns involving CD14, CD11b, CD68, CD8, and FOXP3 as the most informative contributors. Conclusions: Spatial single-cell profiling and IMC-GA-MIL identify spatial immune and stromal features associated with BCG failure. However, findings from both analyses should be considered exploratory and will require validation in larger, independent cohorts.Keywords
Funding Information
- Folke Hermansen Foundation (F-12320-D10192)
- Helse Vest (F-12593-D11698)
This publication has 73 references indexed in Scilit:
- ResNet and its application to medical image processing: Research progress and challengesComputer Methods and Programs in Biomedicine, 2023
- Semi‐automated background removal limits data loss and normalizes imaging mass cytometry dataCytometry Part A, 2021
- Expression of VISTA on tumor-infiltrating immune cells correlated with short intravesical recurrence in non-muscle-invasive bladder cancerCancer Immunology, Immunotherapy, 2021
- Coordinated Cellular Neighborhoods Orchestrate Antitumoral Immunity at the Colorectal Cancer Invasive FrontCell, 2020
- A Structured Tumor-Immune Microenvironment in Triple Negative Breast Cancer Revealed by Multiplexed Ion Beam ImagingCell, 2018
- CD38-NAD+Axis Regulates Immunotherapeutic Anti-Tumor T Cell ResponseCell Metabolism, 2018
- Recurrence of high‐risk bladder cancer: A population‐based analysisCancer, 2013
- Cancer-Related InflammationJournal of Clinical Immunology, 2012
- A note on the Hodges–Lehmann estimatorPharmaceutical Statistics, 2010
- Economic aspects of bladder cancer: what are the benefits and costs?World Journal of Urology, 2009